logo

CING

Cingulate
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Consensus Rating "Strong Buy"
EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About CING

Cingulate Inc.

A biopharmaceutical company that develops Precision Timed Release platform to treat Attention Deficit Hyperactivity Disorder

Pharmaceutical
12/14/2012
12/08/2021
NASDAQ Stock Exchange
13
12-31
Common stock
1901 W. 47th Place, Kansas City, KS 66205
--
Cingulate Inc., was incorporated in Delaware on December 14, 2012. The Company is a clinical-stage biopharmaceutical company leveraging its proprietary Precision Time-Release (PTR) drug delivery platform technology to build and advance a next-generation drug pipeline designed to improve the lives of patients with common diagnostic diseases. The company's PTR platform incorporates a proprietary Erosion Barrier Layer (EBL) designed to allow the release of APIs at specific, predetermined time intervals, unlocking the potential of once-daily, multi-dose tablets.

Company Financials

EPS

CING has released its 2024 Q3 earnings. EPS was reported at -1.83, versus the expected -2.36, beating expectations. The chart below visualizes how CING has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime